Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma

Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel potential therapy for CMM independent of BRAF/NRAS mutation status. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Ishani, Chen, Huiqin, Maddalo, Gianluca, Tuominen, Rainer, Rebecca, Vito W., Herlyn, Meenhard, Hansson, Johan, Davies, Michael A., Egyházi Brage, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576205/
https://www.ncbi.nlm.nih.gov/pubmed/33082316
http://dx.doi.org/10.1038/s41419-020-03097-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576205/
https://www.ncbi.nlm.nih.gov/pubmed/33082316
http://dx.doi.org/10.1038/s41419-020-03097-2

Ejemplares similares